Commense Bio
Boulder, US · Delaware corporation
Commense Bio develops bacterial biotherapeutics using genetically engineered bacteria to treat patients with invasive infectious diseases. It operates in the biotech sector focused on next-generation therapeutics for multiple infectious diseases.
Founders & leadership
TT
Todd TurnerExecutive
Board
RW
Randall W. ViolaBoard director
EP
Erik PrenticeBoard director
JS
Joshua SmithBoard director
JB
Judith BoiceBoard director
NS
N. Stuart HarrisBoard director
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 1 round · 2026
▶$2.5MraisedJun 2026 · 31 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJun 2026 · 31 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
- Todd TurnerExecutive Officer, Director
- Randall W. ViolaDirector
- Erik PrenticeDirector
- Joshua SmithDirector
- Judith BoiceDirector
- N. Stuart HarrisDirector
- Offering amount
- $2.7M
- Amount sold
- $2.5M
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Commense Bio do?
- Commense Bio develops bacterial biotherapeutics using genetically engineered bacteria to treat patients with invasive infectious diseases. It operates in the biotech sector focused on next-generation therapeutics for multiple infectious diseases.
- How much funding has Commense Bio raised?
- Commense Bio has disclosed $2.5M raised across 1 round.
- Where is Commense Bio headquartered?
- Commense Bio is headquartered in Boulder, US.